Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses
Wang D, Bayliss S, Meads C
Record ID 32010000263
English
Authors' objectives:
The objective of this report was to use systematic review evidence to estimate the cost-effectiveness of immunoprophylaxis of RSV using palivizumab in different subgroups of children with or without CLD or CHD who are at high risk of serious morbidity from RSV infection.
Authors' recommendations:
Study found that prophylaxis with palivizumab does not represent good value for money based on the current UK incremental cost-effectiveness ratio threshold of £30,000/quality-adjusted life-year when used unselectively in pre-term infants without chronic lung disease (CLD)/congenital heart disease (CHD) or children with CLD or CHD.
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/2056
Year Published:
2011
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antibodies, Monoclonal
- Antiviral Agents
- Infant
- Infant, Newborn
- Respiratory Syncytial Virus Infections
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2011 Queen’s Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.